Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,292 papers from all fields of science
Search
Sign In
Create Free Account
refractory plasma cell neoplasm
Known as:
Refractory Multiple Myeloma
, Refractory Plasma Cell Myeloma
, plasma cell neoplasm, refractory
A plasma cell neoplasm that is resistant to treatment.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
35 relations
Anemia
Atypical lymphocyte
B lymphoblast
B-Lymphocytes
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.
J. Berdeja
,
Yi Lin
,
+11 authors
J. Kochenderfer
2017
Corpus ID: 79784883
3010Background: To test the safety and efficacy of the CAR T cell modality in relapsed/refractory multiple myeloma (MM), we have…
Expand
2015
2015
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
T. Plesner
,
H. Arkenau
,
+15 authors
P. Richardson
2015
Corpus ID: 79293761
![Graphic][1] Introduction : Daratumumab (DARA) is a human anti-CD38 IgG1κ monoclonal antibody that showed synergistic anti…
Expand
Highly Cited
2013
Highly Cited
2013
Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
J. Gaultney
,
M. Franken
,
+4 authors
C. U. Uyl‐de Groot
Journal of Clinical Pharmacy and Therapeutics
2013
Corpus ID: 39614176
What is known and objective: High costs of novel agents increasingly put pressure on limited healthcare budgets. Demonstration…
Expand
Highly Cited
2012
Highly Cited
2012
The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells
H. Landau
,
S. Mcneely
,
+6 authors
G. Schwartz
Molecular Cancer Therapeutics
2012
Corpus ID: 16274400
DNA cross-linking agents are frequently used in the treatment of multiple myeloma–generating lesions, which activate checkpoint…
Expand
Highly Cited
2011
Highly Cited
2011
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
B. Holkova
,
E. Perkins
,
+18 authors
S. Grant
Clinical Cancer Research
2011
Corpus ID: 1693071
Purpose: A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the…
Expand
Highly Cited
2010
Highly Cited
2010
Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
A. Mahindra
,
P. Richardson
,
+7 authors
N. Raje
2010
Corpus ID: 73961229
8032 Background: Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or relapsed/refractory…
Expand
Highly Cited
2007
Highly Cited
2007
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group…
A. Suvannasankha
,
C. Fausel
,
+7 authors
R. Abonour
The Oncologist
2007
Corpus ID: 12857633
Thalidomide has direct antimyeloma and immunomodulatory effects. In addition, both thalidomide and metronomic chemotherapy…
Expand
Highly Cited
2005
Highly Cited
2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
J. Berenson
,
S. Jagannath
,
+14 authors
K. Anderson
Cancer
2005
Corpus ID: 34947728
Bortezomib, a first‐in‐class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma.
Highly Cited
2002
Highly Cited
2002
The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma.
R. García-Sanz
,
M. I. González-Fraile
,
M. Sierra
,
C. López
,
Marcos González
,
J. S. San Miguel
The Hematology Journal
2002
Corpus ID: 46364652
INTRODUCTION Thalidomide has recently proven to be a useful drug for treatment of refractory and relapsed multiple myeloma…
Expand
Highly Cited
2000
Highly Cited
2000
Thalidomide for resistant and relapsing myeloma
R. Alexanian
,
D. Weber
2000
Corpus ID: 70458315
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE